Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07397611 2026-02-09

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2 Not yet recruiting

32 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07393867 2026-02-06

ARPEGGIO

Phase 2 Not yet recruiting

23 enrolled

Genitourinary

Prostatic Neoplasms

NCT07387510 2026-02-04

DGPR1008-04

Phase 2 Not yet recruiting

27 enrolled

Genitourinary

Prostate Cancer Patients Undergoing Radical Prostatectomy

NCT07223385 2026-02-03

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

Phase 2 Not yet recruiting

80 enrolled

Genitourinary

Disease, Prostatic Neoplasms

NCT07365423 2026-01-29

TerbinaPro

Phase 2 Not yet recruiting

42 enrolled

Genitourinary

Prostatic Neoplasms

NCT06836726 2026-01-28

EVO

Phase 2 Not yet recruiting

35 enrolled

Genitourinary

Castration Resistant Prostate Cancer

NCT07364071 2026-01-27

SENTRY

Phase 2 Not yet recruiting

150 enrolled

Genitourinary

Prostatic Neoplasms

NCT07354594 2026-01-21

ARREST

Phase 2 Not yet recruiting

120 enrolled

Genitourinary

Prostate Cancer Metastatic Castration-Resistant

NCT07354919 2026-01-21

AxeCan

Phase 2 Not yet recruiting

34 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07346404 2026-01-16

RUBIKID

Phase 2 Not yet recruiting

50 enrolled

Genitourinary

Carcinoma, Renal Cell, Neovascularization, Pathologic

NCT07310433 2025-12-30

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

Phase 2 Not yet recruiting

60 enrolled

Genitourinary

Prostatic Neoplasms

NCT07300566 2025-12-24

FORWARD

Phase 2 Not yet recruiting

58 enrolled

Genitourinary

Prostatic Neoplasms

NCT07279597 2025-12-19

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Phase 2 Not yet recruiting

45 enrolled

Genitourinary

Muscle-invasive Bladder Urothelial Carcinoma

NCT07291557 2025-12-18

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

Phase 2 Not yet recruiting

250 enrolled

Genitourinary

Prostatic Neoplasms

NCT07282197 2025-12-15

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

Phase 2 Not yet recruiting

40 enrolled

Genitourinary

Prostatic Neoplasms

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Phase 2 Not yet recruiting

36 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07268794 2025-12-08

CONVERT-HB1

Phase 2 Not yet recruiting

112 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07257718 2025-12-02

FUTURE

Phase 2 Not yet recruiting

262 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07256223 2025-12-01

A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread

Phase 2 Not yet recruiting

30 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07251829 2025-11-26

Neoadjuvant Embolization and Cytoreduction in Prostate Cancer

Phase 2 Not yet recruiting

35 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT07164794 2025-11-19

Memantine Hydrochloride in Prostate Cancer Patients

Phase 2 Not yet recruiting

15 enrolled

Genitourinary

Prostatic Neoplasms

NCT07237269 2025-11-19

Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy

Phase 2 Not yet recruiting

140 enrolled

Genitourinary

Prostatic Neoplasms

NCT06822010 2025-11-14

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Phase 2 Not yet recruiting

28 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06536374 2025-11-12

Folate Study in Men With Advanced Prostate Cancer

Phase 2 Not yet recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms

NCT07226544 2025-11-10

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

Phase 2 Not yet recruiting

31 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07226713 2025-11-10

POSTPONE

Phase 2 Not yet recruiting

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT07218666 2025-10-21

NAPOLEON

Phase 2 Not yet recruiting

30 enrolled

Genitourinary

Aggressive Variant Prostate Carcinoma

NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Phase 2 Not yet recruiting

35 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

106 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07037004 2025-09-23

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Phase 2 Not yet recruiting

62 enrolled

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

ANDARP

TRIFECTA

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

CAIX PET/CT

TeLuNa

PRELUDE

AVESEC

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

CHINANEO

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

SPARCC

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Patients With Recurrent Prostate Cancer After Prostatectomy

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

ARPEGGIO

DGPR1008-04

High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)

TerbinaPro

EVO

SENTRY

ARREST

AxeCan

RUBIKID

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

FORWARD

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

CONVERT-HB1

FUTURE

A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread

Neoadjuvant Embolization and Cytoreduction in Prostate Cancer

Memantine Hydrochloride in Prostate Cancer Patients

Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Folate Study in Men With Advanced Prostate Cancer

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

POSTPONE

NAPOLEON

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

OHAI-NMIBC-01

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery